| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Research Grade Inbakicept
CAS:2135939-52-3
Purity:>95%;1mg/ml Package:100ug;1mg;20mg
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Inbakicept
CAS:2135939-52-3
Purity:95% SDS-PAGE Package:1mg;100ug
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Inbakicept
CAS:2135939-52-3
Purity:98.94% Package:1removed
|
Research Grade Inbakicept (DHE28302) manufacturers
- Inbakicept
-
- $799.00
-
2026-07-27
- CAS:2135939-52-3
- Purity: 98.94%
- Supply Ability: 10g
|
| | Research Grade Inbakicept (DHE28302) Basic information |
| Product Name: | Research Grade Inbakicept (DHE28302) | | Synonyms: | Research Grade Inbakicept (DHE28302);Research Grade Inbakicept;Inbakicept;Interleukin 15 receptor α chain (human sushi domain-containing fragment) fusion protein with immunoglobulin G1 (human Fc fragment), dimer (ACI) | | CAS: | 2135939-52-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Research Grade Inbakicept (DHE28302) Structure]() |
| | Research Grade Inbakicept (DHE28302) Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Research Grade Inbakicept (DHE28302) Usage And Synthesis |
| Uses | Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells[1]. | | in vivo | Inbakicept (0.2 mg/kg; i.v.; twice weekly, for 2 weeks) enhances rituximab-directed protection from a lethal Daudi lymphoma challenge in mouse model[1].
| Animal Model: | SCID mice with Daudi models[1] | | Dosage: | 0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg | | Administration: | Intravenous injection; twice weekly, for 2 weeks | | Result: | Enhanced rituximab-directed control of Raji lymphoma challenge. |
| | IC 50 | IL-15Rα | | References | [1] Rosario M, et al. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res. 2016 Feb 1;22(3):596-608. DOI:10.1158/1078-0432.CCR-15-1419 |
| | Research Grade Inbakicept (DHE28302) Preparation Products And Raw materials |
|